Literature DB >> 20194531

Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.

Brian G Blair1, Christopher A Larson, Preston L Adams, Paolo B Abada, Roohangiz Safaei, Stephen B Howell.   

Abstract

Down-regulation of copper transporter 1 (CTR1) reduces uptake and sensitivity, whereas down-regulation of CTR2 enhances both. Cisplatin (DDP) triggers the rapid degradation of CTR1 and thus limits its own accumulation. We sought to determine the effect of DDP and copper on the expression of CTR2. Changes in CTR1 and CTR2 mRNA and protein levels in human ovarian carcinoma 2008 cells and ATOX1(+/+) and ATOX1(-/-) mouse embryo fibroblasts in response to exposure to DDP and copper were measured by quantitative reverse transcriptase-polymerase chain reaction, Western blot analysis, and deconvolution microscopy. DDP triggered rapid degradation of CTR1 in 2008 human ovarian cancer cells. However, it increased the expression of CTR2 mRNA and protein levels. Expression of CTR2 was heavily modulated by changes in intracellular copper concentration; copper depletion produced rapid disappearance of CTR2, whereas excess copper increased the level of CTR2 protein. This increase was associated with an increase in CTR2 mRNA and prolongation of the CTR2 half-life. Consistent with prior observations that short hairpin RNA interference-mediated knockdown of CTR2 enhanced DDP uptake and tumor cell kill, reduction of CTR2 by copper starvation also enhanced DDP uptake and cytotoxicity. Comparison of the ability of copper and DDP to modulate the expression of CTR1 in ATOX1(+/+) and ATOX1(-/-) indicated that ATOX1 participates in the regulation of CTR2 expression. Unlike CTR1, the expression of CTR2 is increased rather than decreased by DDP. Therefore, these two copper transporters have opposite effects on DDP sensitivity. CTR2 expression is regulated by copper availability via the copper-dependent regulator ATOX1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194531      PMCID: PMC2879916          DOI: 10.1124/mol.109.062836

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  Metal transporters that contribute copper to metallochaperones in Saccharomyces cerevisiae.

Authors:  M E Portnoy; P J Schmidt; R S Rogers; V C Culotta
Journal:  Mol Genet Genomics       Date:  2001-07       Impact factor: 3.291

2.  Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase.

Authors:  Iqbal Hamza; Joseph Prohaska; Jonathan D Gitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

3.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

4.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.

Authors:  Seiko Ishida; Jaekwon Lee; Dennis J Thiele; Ira Herskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

5.  The internalization and degradation of human copper transporter 1 following cisplatin exposure.

Authors:  Alison K Holzer; Stephen B Howell
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

6.  Ctr6, a vacuolar membrane copper transporter in Schizosaccharomyces pombe.

Authors:  Daniel R Bellemare; Lance Shaner; Kevin A Morano; Jude Beaudoin; Rejean Langlois; Simon Labbe
Journal:  J Biol Chem       Date:  2002-09-18       Impact factor: 5.157

7.  Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.

Authors:  Alison K Holzer; Kuniyuki Katano; Leo W J Klomp; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Authors:  Alison K Holzer; Goli Samimi; Kuniyuki Katano; Wiltrud Naerdemann; Xinjian Lin; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2004-06-30       Impact factor: 4.436

9.  Functional properties of the human copper-transporting ATPase ATP7B (the Wilson's disease protein) and regulation by metallochaperone Atox1.

Authors:  Svetlana Lutsenko; Ruslan Tsivkovskii; Joel M Walker
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

10.  The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.

Authors:  Xinjian Lin; Tsuyoshi Okuda; Alison Holzer; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

View more
  20 in total

1.  Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage.

Authors:  Wai-Kin Yu; Zhigang Wang; Chi-Chun Fong; Dandan Liu; Tak-Chun Yip; Siu-Kie Au; Guangyu Zhu; Mengsu Yang
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

2.  Role of the cellular prion protein in the neuron adaptation strategy to copper deficiency.

Authors:  Emanuela Urso; Daniela Manno; Antonio Serra; Alessandro Buccolieri; Antonia Rizzello; Antonio Danieli; Raffaele Acierno; Benedetto Salvato; Michele Maffia
Journal:  Cell Mol Neurobiol       Date:  2012-02-24       Impact factor: 5.046

3.  Comparison of N-acetylmethionine reactivity between oxaliplatin and an oxaliplatin derivative with chiral (S,S) amine nitrogen atoms.

Authors:  Kevin M Williams; Amy D Poynter; Jonathan D Hendrie; Daniel C Jackson; Virginia K Martin
Journal:  Inorganica Chim Acta       Date:  2013-05-24       Impact factor: 2.545

4.  Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.

Authors:  Kristin M Bompiani; Cheng-Yu Tsai; Felix P Achatz; Janika K Liebig; Stephen B Howell
Journal:  Metallomics       Date:  2016-05-09       Impact factor: 4.526

Review 5.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

6.  Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.

Authors:  Paolo B Abada; Christopher A Larson; Gerald Manorek; Preston Adams; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2012-06-18       Impact factor: 4.436

7.  Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.

Authors:  Carlos P Huang; Mariama Fofana; Jefferson Chan; Christopher J Chang; Stephen B Howell
Journal:  Metallomics       Date:  2014-02-13       Impact factor: 4.526

8.  Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.

Authors:  Cheng-Yu Tsai; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Biochem Pharmacol       Date:  2014-06-23       Impact factor: 5.858

9.  Mechanistic basis for overcoming platinum resistance using copper chelating agents.

Authors:  Zheng D Liang; Yan Long; Wen-Bin Tsai; Siqing Fu; Razelle Kurzrock; Mihai Gagea-Iurascu; Fan Zhang; Helen H W Chen; Bryan T Hennessy; Gordon B Mills; Niramol Savaraj; Macus Tien Kuo
Journal:  Mol Cancer Ther       Date:  2012-08-21       Impact factor: 6.261

10.  Cathepsin Protease Controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-binding Ectodomain.

Authors:  Helena Öhrvik; Brandon Logeman; Boris Turk; Thomas Reinheckel; Dennis J Thiele
Journal:  J Biol Chem       Date:  2016-05-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.